Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 11:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 2,218 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ASCEND Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers

NCT05328557
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
CUG252, Placebo
Drug
Lead sponsor
Cugene Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Results available

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

NCT03095651
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

NCT06453265
View directory record Official record
Conditions
Abuse, Drug
Interventions
Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug, Treatment A:, Treatment B, Treatment C, Qualification
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 18, 2026, 11:14 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

NCT07607964
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
ABBV-519
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Anniston, Alabama • Tustin, California • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects

NCT04508179
View directory record Official record
Conditions
Solid Tumor
Interventions
7HP349 Single Ascending Dose, 7HP349 Multiple Ascending Dose, Placebo Single Ascending Dose, Placebo Multiple Ascending Dose, 7HP349 Food Effect
Drug
Lead sponsor
7 Hills Pharma, LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT02406742
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
CC-122, Ibrutinib, Obinutuzumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 79 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
8
States / cities
La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 18, 2026, 11:14 AM EDT
Not listed Phase 4 Interventional

Remission From Stage D Heart Failure

NCT01774656
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
Pharmacological Treatment
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 59 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Louisville, Kentucky • Omaha, Nebraska • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers

NCT02931214
View directory record Official record
Conditions
Healthy
Interventions
GMI-1359, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
19 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects

NCT05068947
View directory record Official record
Conditions
Phase 1
Interventions
GV101, Placebo
Drug
Lead sponsor
Graviton Bioscience Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486

NCT00117949
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
12
States / cities
Anaheim, California • Laguna Woods, California • San Bernardino, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers

NCT01893528
View directory record Official record
Conditions
Healthy Volunteers
Interventions
REGN2009, placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study of ARRY-371797 in Healthy Subjects

NCT00790049
View directory record Official record
Conditions
Healthy
Interventions
ARRY-371797, p38 inhibitor; oral, Placebo; oral
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 18, 2026, 11:14 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Biphasic Effects of Acute Alcohol Intoxication on Bystander Intervention

NCT05701865
View directory record Official record
Conditions
Alcohol Intoxication
Interventions
Alcohol Intoxication- Ascending Limb, Alcohol Intoxication- Descending Limb, No Alcohol Control
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 30 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 18, 2026, 11:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

XTX301 in Patients With Advanced Solid Tumors

NCT05684965
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
XTX301
Drug
Lead sponsor
Xilio Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Sacramento, California • New Haven, Connecticut • Saint Louis Park, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 18, 2026, 11:14 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa

NCT06361836
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
SBT777101
Biological
Lead sponsor
Sonoma Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

NCT01919684
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LGD-6972, Placebo (Captisol®)
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 18, 2026, 11:14 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy

NCT02310763
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
PF-06252616, Placebo
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 15 Years · Male only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 18, 2026, 11:14 AM EDT
Active, not recruiting Not applicable Interventional

PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection

NCT05174767
View directory record Official record
Conditions
Acute Aortic Dissection
Interventions
AMDS
Device
Lead sponsor
Artivion Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3154207 in Healthy Participants

NCT02365571
View directory record Official record
Conditions
Healthy Participants
Interventions
LY3154207, Placebo, Itraconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 18, 2026, 11:14 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

NCT06381141
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CLN-619
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730

NCT03054194
View directory record Official record
Conditions
Healthy Participants
Interventions
E2730, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Oral YUQ-A1007 in Healthy Volunteers

NCT06835296
View directory record Official record
Conditions
Healthy
Interventions
YUQ-A1007 is a novel gut-enriched AhR agonist. This compound is undergoing preclinical development, and comprehensive nonclinical studies.
Drug
Lead sponsor
Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Diindolylmethane in Preventing Cancer in Healthy Volunteers

NCT00784394
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
diindolylmethane, placebo, pharmacological study, laboratory biomarker analysis, quality-of-life assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 18, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects

NCT01511783
View directory record Official record
Conditions
Healthy
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 18, 2026, 11:14 AM EDT